BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/3/2025 7:31:04 AM | Browse: 150 | Download: 589
 |
Received |
|
2024-12-13 10:51 |
|
Peer-Review Started |
|
2024-12-13 10:51 |
|
First Decision by Editorial Office Director |
|
2025-01-16 13:30 |
|
Return for Revision |
|
2025-01-16 13:30 |
|
Revised |
|
2025-01-24 11:27 |
|
Publication Fee Transferred |
|
2025-01-28 10:06 |
|
Second Decision by Editor |
|
2025-02-10 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-10 08:49 |
|
Articles in Press |
|
2025-02-10 08:49 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-13 03:15 |
|
Publish the Manuscript Online |
|
2025-03-03 07:31 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Parimal Lawate, Virender Chauhan, L Rajendra Prasad, Abhimanrao Pawar, Atul G Puranik, Alok Bansal, Abhiram Koganti, Ashok Jaiswal, Pranali Puradkar and Kunal Jhaveri |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kunal Jhaveri, MD, Department of Medical Affairs, Zydus Healthcare Limited, Zydus Tower, CTS 460/6, Village Pahadi Off IB Patel Road, Goregaon East, Mumbai 400063, Mahārāshtra, India. kunal.jhaveri@zyduslife.com |
| Key Words |
Gastroesophageal reflux disease; Heartburn; Acid reflux; Rabeprazole; Dual delayed-release |
| Core Tip |
The novel dual delayed-release formulation of rabeprazole, Happi ER, addresses the unmet needs of gastroesophageal reflux disease (GERD) management by offering both immediate and sustained acid suppression. This real-world evidence study demonstrated significant improvements in heartburn severity, reduced night-time awakenings, and enhanced patient satisfaction, particularly in patients with mild-to-moderate GERD. With a safety profile comparable to that of traditional proton pump inhibitors and superior efficacy in managing nocturnal symptoms, Happi ER provides a comprehensive and reliable solution for long-term GERD management. |
| Publish Date |
2025-03-03 07:31 |
| Citation |
Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2025; 16(1): 103898 |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i1/103898.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i1.103898 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
